MedPath

Alleviant ALLAY-HFrEF Study

Not Applicable
Conditions
Heart Failure
Registration Number
NCT06812533
Lead Sponsor
Alleviant Medical, Inc.
Brief Summary

Prospective, multicenter, randomized, sham-controlled, double blind (patient and observer), study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFrEF.

Detailed Description

Not available

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
350
Inclusion Criteria
  • LVEF ≤ 40%
  • NYHA class II, III or ambulatory IV HF
  • Receiving optimal, maximally tolerated, stable GDMT
Exclusion Criteria
  • Advanced heart failure
  • Life-expectancy < 12 months
  • Evidence of right heart dysfunction

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Composite Primary Endpoint12-Month

The primary endpoint is a composite of all-cause mortality or cardiac transplantation or permanent left ventricular assist device (LVAD) and heart failure events.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (21)

University of California San Francisco

🇺🇸

San Francisco, California, United States

Atlanta VA Health Care System

🇺🇸

Decatur, Georgia, United States

Midwest Cardiovascular Institute

🇺🇸

Naperville, Illinois, United States

University Medical Center New Orleans

🇺🇸

New Orleans, Louisiana, United States

Tufts Medical Center

🇺🇸

Boston, Massachusetts, United States

Boston Medical Center

🇺🇸

Boston, Massachusetts, United States

Washington University - St Louis

🇺🇸

Saint Louis, Missouri, United States

Stony Brook Medicine

🇺🇸

New York, New York, United States

NC Heart and Vascular Research

🇺🇸

Raleigh, North Carolina, United States

Pinnacle Health Cardiovascular Institute

🇺🇸

Harrisburg, Pennsylvania, United States

Scroll for more (11 remaining)
University of California San Francisco
🇺🇸San Francisco, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.